Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension (to lower blood pressure, alone or in combination with other antihypertensives)
Hypertension
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic via CYP3A4; minor metabolism via other pathways. Excreted in feces (78%) and urine (22%).
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 50% bound to plasma proteins (primarily albumin).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution is approximately 1.7 L/kg, indicating extensive distribution into tissues.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is approximately 2.5% (low due to limited absorption and high first-pass metabolism); absorption is reduced by high-fat meal (by up to 50%).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in GFR <30 m L/min/1.73 m². For GFR ≥30 m L/min/1.73 m², no dose adjustment required.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No dose adjustment required in elderly patients; initiate therapy at 150 mg once daily and monitor renal function and blood pressure closely due to increased risk of hypotension and renal impairment.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Fetal toxicity (avoid in pregnant women; discontinue if pregnancy detected),Hypotension in volume-depleted patients,Renal impairment (monitor renal function; risk of acute renal failure in patients with bilateral renal artery stenosis),Hyperkalemia (especially in patients with renal impairment, diabetes, or on potassium-sparing diuretics),Angioedema (discontinue immediately and manage appropriately)
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Pregnancy,History of angioedema with previous renin-angiotensin system inhibitors,Concomitant use with aliskiren in patients with diabetes (age- and renal-specific restrictions)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
High-fat meals reduce aliskiren absorption; avoid consistent consumption with high-fat foods. Grapefruit juice may decrease aliskiren levels; avoid concurrent intake. No other significant food interactions.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. First trimester exposure may also carry increased risk but is less well-defined.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
No data on presence in human milk; manufacturer advises against breastfeeding due to potential adverse effects in nursing infants, including hypotension and renal impairment.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustments recommended; avoid use in pregnancy, especially during second and third trimesters, due to risk of fetal harm. If pregnancy occurs, discontinue promptly.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
TEKTURNA (aliskiren) is a direct renin inhibitor used for hypertension. Monitor renal function and potassium levels due to risk of hyperkalemia and renal impairment, especially in patients with diabetes, renal artery stenosis, or concomitant ACE/ARB use. Avoid use during pregnancy (category D). Contraindicated with cyclosporine and itraconazole due to increased aliskiren exposure.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take TEKTURNA once daily with or without food, but consistently either with a meal or without.,Avoid high-fat meals as they can reduce absorption.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not use salt substitutes containing potassium without consulting your doctor.,Report symptoms like muscle cramps, irregular heartbeat, or weakness (signs of hyperkalemia).,Stay hydrated and avoid dehydration (vomiting, diarrhea, excessive sweating) as it may increase side effects.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA vs ALDORIL D30, answered by our medical review team.
TEKTURNA is a Antihypertensive that works by Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA is: 150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.